CD274 and lung carcinoma: Immune checkpoint blockade (ICB)-based immunotherapy, which includes treatments of anti-programmed death 1 (PD-1) as well as anti-programmed death-ligand 1 (PD-L1), has significantly transformed the treatment landscape for lung cancer by reactivating dormant antitumor T-cell effector responses [1, 2].